Actavis drug producer, which owns the former Sindan plantacquired in a deal worth almost 150m euros in 2006, expects exportsof 5 or 6m euros to the US market this year, which could become thecompany's biggest export market. In 2009, exports to this marketwere insignificant. "In terms of exports, we expect 15-20% growththis year, while with the rest of projections we're cautiousbecause of regulations," said Alina Culcea, general manager ofActavis Romania. The company last year generated turnover worthmore than 107m euros domestically, down from 2008 as a result ofthe sliding market share and of the arrival of new players, and for2010 the company has budgeted flat turnover. Actavis' exports in2009 reached 28m euros and targeted areas such as the US, Japan,the EU, Australia, and South Africa. "Last year, we had a 10-15%profit margin, but in 2010 we'll be hurt by current measures and wehave more cautious projections, of around 10%," Culcea also said.In 2010, the plant has earmarked investments worth around 2.5meuros in upgrading as it operates at over 80% of its capacity.
Pentru alte știri, analize, articole și informații din business în timp real urmărește Ziarul Financiar pe WhatsApp Channels
